Pharmacology and Therapeutic Hypothermia



Various randomized clinical trials have demonstrated the beneficial effects of therapeutic hypothermia on survival and neurological function following cardiac arrest [1–4]. Despite these well-documented outcomes, a number of physiologic and metabolic complications have been identified [see  Chap. 8] [5]. More specifically, data examining the impact of reducing patients’ core body temperature to 32–34°C on drug disposition and therapeutic response remains incomplete [6–8]. Given the number of pharmacologic agents provided to patients following cardiac arrest, knowledge of the impact of therapeutic hypothermia on their pharmacokinetic, pharmacodynamic, efficacy and safety parameters is paramount. This chapter includes an in-depth review of both animal and human data as well as provides recommendations for clinical use for pharmacologic agents routinely used in the management of patients undergoing therapeutic hypothermia following cardiac arrest.


Aspirin Cyanide Propranolol Vancomycin Gentamicin 


  1. 1.
    Hachimi-Idrissi S, Corne L, Ebinger G, et al. Mild hypothermia induced by a helmet device: a clinical feasibility study. Resuscitation. 2001;51:275–81.CrossRefPubMedGoogle Scholar
  2. 2.
    HACA Investigators. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549–56.CrossRefGoogle Scholar
  3. 3.
    Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557–63.CrossRefPubMedGoogle Scholar
  4. 4.
    Lundbye JB, Rai M, Ramu B, et al. Therapeutic hypothermia is associated with improved neurologic outcomes and survival in cardiac arrest survivors of non-shockable rhythms. Resuscitation. 2012;83:202–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Polderman KH. Mechamisms of action, physiologic effects, and complications of hypothermia. Crit Care Med. 2009;37(7 Suppl):S186–202.CrossRefPubMedGoogle Scholar
  6. 6.
    Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med. 2007;35:2196–204.CrossRefPubMedGoogle Scholar
  7. 7.
    Van den Broek MP, Groenendaal F, Egberts AC, et al. Effects of hypothermia on pharmacokinetics and pharmacodynamics. A systematic review of preclinical and clinical studies. Clin Pharmacokinet. 2010;49:277–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhou J, Poloyac SM. The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function. Expert Opin Drug Metab Toxicol. 2011;7:803–16.CrossRefPubMedGoogle Scholar
  9. 9.
    Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001;58:737–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35:361–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Fritz HG, Holzmary M, Walter B, et al. The effect of mild hypothermia on plasma fentanyl concentration and biotransformation in juvenile pigs. Anesth Analg. 2005;100:996–1002.CrossRefPubMedGoogle Scholar
  12. 12.
    Gepts E, Camu F, Cockshott I, et al. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg. 1987;66:1256–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Morgan DJ, Campbell GA, Crankshaw DP. Pharmacokinetics of propofol when given by intravenous infusion. Br J Clin Pharmacol. 1990;30:144–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Cockshott I, Douglas E, Prys-Roberts C, et al. The pharmacokinetics of propofol during and after intravenous infusion in man. Eur J Anaesthesiol. 1990;7:265–75.Google Scholar
  15. 15.
    Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30:119–41.CrossRefPubMedGoogle Scholar
  16. 16.
    Leslie K, Sessler DI, Bjorksten AR, et al. Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium. Anesth Analg. 1995;80:1007–14.PubMedGoogle Scholar
  17. 17.
    Kang TM. Propofol infusion syndrome in critically ill patients. Ann Pharmacother. 2002;36:1453–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Fukuoka N, Aibiki M, Tsukamoto T, et al. Biphasic concentration change during continuous midazolam administration in brain-injured patients undergoing therapeutic moderate hypothermia. Resuscitation. 2004;60:225–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Hostler D, Zhou J, Tortorici MA. Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. Drug Metab Dispos. 2010;38:781–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Ariano RE, Kassum DA, Aronson KJ. Comparison of sedative recovery time after midazolam versus diazepam administration. Crit Care Med. 1994;22:1492–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Malacrida R, Fritz ME, Suter P, et al. Pharmacokinetics of midazolam administered by continuous infusion to intensive care patients. Crit Care Med. 1992;20:1123–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Bauer TM, Ritz R, Haberthur C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995;246:145–7.CrossRefGoogle Scholar
  23. 23.
    Chamorro C, Borrallo JM, Romera MA, et al. Anesthesia and analgesia protocol during therapeutic hypothermia after cardiac arrest: a systematic review. Anesth Analg. 2010;110:1328–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Holzer M. Targeted temperature management of comatose survivors of cardiac arrest. N Engl J Med. 2010;363:1256–64.CrossRefPubMedGoogle Scholar
  25. 25.
    Nolan JP, Neumar RW, Adrie C, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A scientific statement from the International Liaison Committee on Resuscitaiton; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. Resuscitation. 2008;19:350–9.CrossRefGoogle Scholar
  26. 26.
    Castren M, Silfvast T, Rubertsson S, et al. Scandinavian clinical practice guidelines for therapeutic hypothermia and post-resuscitation care after cardiac arrest. Acta Anaesthesiol Scand. 2009;53:280–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002;30:142–56.CrossRefPubMedGoogle Scholar
  28. 28.
    Warr J, Thiboutot Z, Rose L, et al. Current therapeutic uses, pharmacology, and clinical considerations of neuromuscular blocking agents for critically ill adults. Ann Pharmacother. 2011;45:1116–26.CrossRefPubMedGoogle Scholar
  29. 29.
    Heier T, Caldwell JE. Impact of hypothermia on the response to neuromuscular blocking drugs. Anesthesiology. 2006;104:1070–80.CrossRefPubMedGoogle Scholar
  30. 30.
    Miller RD, Agoston S, van der Pol F, et al. Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. J Pharmacol Exp Ther. 1978;207:532–8.PubMedGoogle Scholar
  31. 31.
    Horrow JC, Bartkowski RR. Pancuronium, unlike other nondepolarizing relaxants, retains potency at hypothermia. Anesthesiology. 1983;58:357–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Beaufort TM, Proost JH, Maring JG, et al. Effect of hypothermia on the hepatic uptake and biliary excretion of vecuronium in the isolated perfused rat liver. Anesthesiology. 2001;94:270–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Heier T, Caldwell JE, Sessler D, et al. Mild intraoperative hypothermia increases duration of action and spontaneous recovery of vecuronium blockade during nitrous oxide-isoflurane anesthesia in humans. Anesthesiology. 1991;74:815–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Heier T, Caldwell JE, Sharma ML, et al. Mild intraoperative hypothermia does not change the pharmacodynamics (concentration-effect relationship) of vecuronium in humans. Anesth Analg. 1994;78:973–7.Google Scholar
  35. 35.
    Caldwell JE, Heier T, Wright PMC, et al. Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology. 2000;92:84–93.CrossRefPubMedGoogle Scholar
  36. 36.
    Cammu G, Coddens J, Hendrickx J, et al. Dose requirements of infusions of Cisatracurium or ­rocuronium during hypothermic cardiopulmonary bypass. Br J Anaesth. 2000;84:897–90.CrossRefGoogle Scholar
  37. 37.
    Denny NM, Kneeshaw JD. Vecuronium and atracurium infusions during hypothermic cardiopulmonary bypass. Anaesthesia. 1986;41:919–22.CrossRefPubMedGoogle Scholar
  38. 38.
    Buzello W, Schluermann D, Schindler M, et al. Hypothermic cardiopulmonary bypass and neuromuscular blockade by pancuronium and vecuronium. Anesthesiology. 1985;62:201–4.CrossRefPubMedGoogle Scholar
  39. 39.
    Diefenbach C, Abel M, Buzello W. Greater neuromuscular blocking potency of atracurium during hypothermic than during normothermic cardiopulmonary bypass. Anesth Analg. 1992;75:275–8.CrossRefGoogle Scholar
  40. 40.
    Futter EM, Whalley DG, Wunands JE, et al. Pancuronium requirements during hypothermic cardiopulmonary bypass in man. Anaesth Intensive Care. 1983;11:216–9.PubMedGoogle Scholar
  41. 41.
    Smeulers NJ, Wierda MKJ, van den Boek L, et al. Effects of hypothermic cardiopulmonary bypass on the pharmacodynamics and pharmacokinetics of rocuronium. J Cardiothorac Vasc Anesth. 1995;9:700–5.CrossRefPubMedGoogle Scholar
  42. 42.
    McClain DA, Hugg CC. Intravenous fentanyl kinetics. Clin Pharmacol Ther. 1980;28:106–14.CrossRefPubMedGoogle Scholar
  43. 43.
    Koren G, Barker C, Goresky G, et al. The influence of hypothermia on the disposition of fentanyl – human and animal studies. Eur J Clin Pharmacol. 1987;32:373–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Statler KD, Alexander HL, Vagni VA, et al. Moderate hypothermia may be detrimental after traumatic brain injury in fentanyl-anesthetized rats. Crit Care Med. 2003;31:1134–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Fritz HG, Holzmayr M, Walter B, et al. The effect of mild hypothermia on plasma fentanyl concentration and biotransformation in juvenile pigs. Anesth Analg. 2005;100:996–1002.CrossRefPubMedGoogle Scholar
  46. 46.
    Empey PE, Miller TM, Philbrick AH, et al. Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest. Crit Care Med. 2012;40:1221–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Koska AJ, Romagnoli A, Kramer WG. Effect of cardiopulmonary bypass on fentanyl distribution and elimination. J Pharmacol Ther. 1981;29:100–5.Google Scholar
  48. 48.
    Koska AJ, Romagnoli A, Kramer WG. Pharmaco­dynamics of fentanyl citrate in patients undergoing aortocoronary bypass. Cardiovasc Dis. 1981;8:405–12.PubMedGoogle Scholar
  49. 49.
    Gruber EM, Laussen PC, Costa A, et al. Stress response in infants undergoing cardiac surgery: a randomized study of fentanyl bolus, fentanyl infusion, and fentanyl-midazolam infusion. Anesth Analg. 2001;92:882–90.CrossRefPubMedGoogle Scholar
  50. 50.
    Kussman BD, Zurakowski D, Sullivan L, et al. Evaluation of plasma fentanyl concentrations in infants during cardiopulmonary bypass with low-­volume circuits. J Cardiothorac Vasc Anesth. 2005;19:316–21.CrossRefPubMedGoogle Scholar
  51. 51.
    Ruggeri L, Landoni G, Guarracino F, et al. Remifentanil in critically ill cardiac patients. Ann Card Anaesth. 2011;14:6–12.PubMedGoogle Scholar
  52. 52.
    Burkle H, Dunbar S, Van Aken H. Remifentanil: a novel, short-acting, mu-opioid. Anesth Analg. 1996;83:646–51.PubMedGoogle Scholar
  53. 53.
    Russell D, Royston D, Rees PH, et al. Effect of temperature and cardiopulmonary bypass on the pharmacokinetics of remifentanil. Br J Anaesth. 1997;79:456–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Michelsen LG, Golford NHG, Lu W, et al. The pharmacokinetics of remifentanil in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Anesth Analg. 2001;93:1100–5.CrossRefPubMedGoogle Scholar
  55. 55.
    Puig MM, Warner W, Tang CK, et al. Effects of temperature on the interaction of morphine with opioid receptors. Br J Anaesth. 1987;59:1459–64.CrossRefPubMedGoogle Scholar
  56. 56.
    Bansinath M, Turndorf H, Puig MM. Influence of hypo and hyperthermia on disposition of morphine. J Clin Pharmacol. 1988;28:860–4.PubMedGoogle Scholar
  57. 57.
    Roka A, Melinda KT, Vasarhelyi B, et al. Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. Pediatrics. 2008;121:e844–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Nielsen N, Hovdenes J, Nilsson F, et al. Outcome, timing, and adverse events in therapeutic hypothermia after out-of-hospital cardiac arrest. Acta Anaesthesiol Scand. 2009;53:926–34.CrossRefPubMedGoogle Scholar
  59. 59.
    Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):670S–707.CrossRefPubMedGoogle Scholar
  60. 60.
    Frelinger AL, Furman MI, Barnard MR, et al. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. Am J Cardiol. 2003;92:1099–101.CrossRefPubMedGoogle Scholar
  61. 61.
    Michelson AD, MacGregor H, Barnard MR, et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost. 1994;71:633–40.PubMedGoogle Scholar
  62. 62.
    Michelson AD, Barnard MR, Khuri SF, et al. The effects of aspirin and hypothermia on platelet function in vivo. Br J Haematol. 1999;104:64–8.CrossRefPubMedGoogle Scholar
  63. 63.
    Lindenblatt N, Menger MD, Klar E, et al. Sustained hypothermia accelerates microvascular thrombus formation in mice. Am J Physiol Heart Circ Physiol. 2005;289:H2680–7.CrossRefPubMedGoogle Scholar
  64. 64.
    Xavier G, Kalb M, Marschalek C, et al. The effects of test temperature and storage temperature on platelet aggregation: a whole blood in vitro study. Anesth Analg. 2006;102:1280–4.CrossRefGoogle Scholar
  65. 65.
    Hogberg C, Erlinge D, Braun OO. Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment. Thromb J. 2009;7:2.CrossRefPubMedGoogle Scholar
  66. 66.
    Bjelland TW, Hjertner O, Klepstad P, et al. Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2010;81:1627–31.CrossRefPubMedGoogle Scholar
  67. 67.
    Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2001;45:1157–64.CrossRefGoogle Scholar
  68. 68.
    O’Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: clopidogrel: does on size fit all? Circulation. 2006;114:e600–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Han YS, Tveita T, Kondratiev TV, et al. Changes in cardiovascular β-adrenoceptor responses during hypothermia. Cryobiology. 2008;57:246–50.CrossRefPubMedGoogle Scholar
  70. 70.
    McAllister RG, Bourne DW, Tan TG, et al. Effects of hypothermia on propranolol kinetics. Clin Pharmacol Ther. 1979;25:1–7.PubMedGoogle Scholar
  71. 71.
    Carmona MJC, Malbouisson LMS, Pereira VA, et al. Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery. Braz J Med Biol Res. 2005;38:713–21.CrossRefPubMedGoogle Scholar
  72. 72.
    Carmona MJC, Pereira VA, Malbouisson LMS, et al. Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. Braz J Med Biol Res. 2009;42:574–81.CrossRefPubMedGoogle Scholar
  73. 73.
    Booth BP, Brien JF, Marks GS, et al. The effects of hypothermic and normothermic cardiopulmonary bypass on glyceryl trinitrate activity. Anesth Analg. 1994;78:848–56.CrossRefPubMedGoogle Scholar
  74. 74.
    Smith RP, Kruszyana H. Nitroprusside produces cyanide poisoning via a reaction with hemoglobin. J Pharmacol Exp Ther. 1974;191:557–63.PubMedGoogle Scholar
  75. 75.
    Tinker JH, Michenfelder JD. Sodium nitroprusside: pharmacology, toxicology, and therapeutics. Anesthesiology. 1976;45:349–54.Google Scholar
  76. 76.
    Moore RA, Guller EA, Gallagher JD, et al. Effect of hypothermic cardiopulmonary bypass on nitroprusside metabolism. Clin Pharmacol Ther. 1985;37:680–3.CrossRefPubMedGoogle Scholar
  77. 77.
    Wotkyns RS, Hirose H, Eiseman B. Prolonged hypothermia in experimental pneumococcal peritonitis. Surg Gynecol Obstet. 1958;107:363–9.PubMedGoogle Scholar
  78. 78.
    Jones JH, Campbell PJ. Penicillin therapy of experimental staphylococcal septicemia in mice exposed to cold. J Pathol Bacteriol. 1962;84:433–7.CrossRefPubMedGoogle Scholar
  79. 79.
    Klamerus KJ, Rodvold KA, Silverman NA, et al. Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition. Antimicrob Agents Chemother. 1988;32:631–5.CrossRefPubMedGoogle Scholar
  80. 80.
    Koren G, Barker C, Bohn D, et al. Influence of hypothermia on the pharmacokinetics of gentamicin and theophylline in piglets. Crit Care Med. 1985;13:844–7.CrossRefPubMedGoogle Scholar
  81. 81.
    Mercer JM, Neyens RR. Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia. Pharmacotherapy. 2010;30:654–60.CrossRefPubMedGoogle Scholar
  82. 82.
    Liu X, Borooah M, Stone J, et al. Serum gentamicin concentrations in encephalopathic infants are not affected by therapeutic hypothermia. Pediatrics. 2009;124:310–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2012

Authors and Affiliations

  1. 1.Department of Pharmacy and MedicineUniversity of Connecticut, Schools of Pharmacy and MedicineStorrs, FarmingtonUSA

Personalised recommendations